Supplements
magnesium improves glycemic control
In plain terms: Does magnesium supplementation actually improve blood sugar control?
Part of: 🧪 magnesium
Yes—especially if you're magnesium-deficient or have type-2 diabetes it lowers fasting glucose and insulin resistance, though the HbA1c effect is small and replete people see little.
📅 Last reviewed: 2026-07-15 ⓘ
Evidence ladder
How far up the ladder this claim has climbed. A high consensus on a low rung means "consistent so far," not "proven in people."
Top evidence so far: All trials, pooled (Meta-analysis)
How the studies fall
What the evidence shows
Oral magnesium improves glycemic control — lowering fasting glucose and insulin resistance — in type 2 diabetes, prediabetes, and magnesium-deficient states, confirmed across multiple RCT meta-analyses. Effect concentrates in deficiency/hyperglycemia; the HbA1c change is small (Maqrashi WMD −0.16%, CI touching 0) and euglycemic replete people should not expect much.
The evidence (18)
| Source | Grade | Stance | Quality | Finding |
|---|---|---|---|---|
| ELDerawi WA, Naser IA, Taleb MH, Abutair AS 2018 · Nutrients | RCT | supports | moderate | T2D RCT: Mg supplementation improved glycemic response and insulin indices. ↩ SUPERSEDED — pooled in the review above, counted once |
| Papagiannidou A, Mitropoulou M, Papantzikos K, Petropoulou D, Tsilingiris D, Magkos F, Dalamaga M 2026 · Curr Nutr Rep | observational | supports | low | Narrative review: 'Since this is a narrative review, no formal methodological quality assessment or systematic inclusion criteria were applied.' Glycemic statement re-passes other meta-analyses of RCTs ('modest but clinically relevant improvements'). Review — zero weight. |
| Konur K, Polat HB, Karavar E, Ayaz T 2026 · Endocrine, metabolic & immune disorders drug targets | observational | mixed | low | Retrospective n=502 T2DM; poor glycemic control had lower serum Mg (group difference), but ROC AUC=0.41 (no predictive value) |
| Eriksson J, Kohvakka A 1995 · Ann Nutr Metab | RCT | contradicts | low | NIDDM crossover RCT: Mg gave NO glycemic/lipid benefit (ascorbic acid did); only IDDM BP fell. ↩ SUPERSEDED — pooled in the review above, counted once |
| Zhao B, Deng H, Li B, Chen L, Zou F, Hu L, Wei Y, Zhang W 2020 · Diabetes Metab Res Rev | meta-analysis | supports | moderate | SR + trial-sequential analysis (26 RCTs): Mg reduced FPG (SMD -0.32), 2h-OGTT, fasting insulin, HOMA-IR (-0.41); benefits stable. |
| Talari HR, Zakizade M, Soleimani A, Bahmani F, Ghaderi A, Mirhosseini N, Eslahi M, Babadi M, Mansournia MA, Asemi Z 2019 · Br J Nutr | RCT | supports | moderate | Diabetic haemodialysis RCT (250 mg/d MgO, 24 wk): HbA1c -0.74%, insulin/HOMA-IR down, QUICKI up vs placebo. ↩ SUPERSEDED — pooled in the review above, counted once |
| Rodríguez-Morán M, Guerrero-Romero F 2003 · Diabetes Care | RCT | supports | moderate | Low-Mg T2D RCT (MgCl2 solution): improved insulin sensitivity and metabolic control. ↩ SUPERSEDED — pooled in the review above, counted once |
| Sri B, Mattyvanan S, S R, L C D 2026 · Cureus | observational | supports | low | Cross-sectional n=55 T2DM; hypomagnesemia group HbA1c 9.72±2.85% vs normal-Mg 7.65±1.94% (p=0.011); Mg inversely correlated w/ HbA1c r=-0.41 |
| Basit A, Kumar S, Ahmed H, Babar R, Saeed SS, Siddiqui TA, Khan S, Saeed A, Khan M, Hanif H, Fasih A, Shabbir S, Kumar H, Kumar L, Raja A, Kumar S, Chander S 2026 · J Diabetes Metab Disord | meta-analysis | supports | moderate | SR/MA in prediabetic adults: oral Mg improves glycemic and cardiometabolic outcomes; Mg central to insulin signaling, deficiency linked to insulin resistance. |
| de Lordes Lima M, Cruz T, Pousada JC, Rodrigues LE, Barbosa K, Canguçu V 1998 · Diabetes Care | RCT | supports | low | T2D increasing-dose RCT (MgO): improved metabolic control in hypomagnesemic patients. |
| Maqrashi NA, Busaidi SA, Al-Rasbi S, Alawi AMA, Al-Maqbali JS 2025 · Sultan Qaboos Univ Med J | meta-analysis | supports | moderate | MA 23 RCTs (n=1345): serum Mg +0.69 mmol/L, fasting glucose WMD -0.58 mmol/L; HbA1c only -0.16% (CI -0.32..0.00), larger in age>=65 & longer duration. |
| Yang J, Zhang H, Li Y, Wu W, Pan M, Wang J, Li G, Wu Y, Guo C, Yang L, Ding J, Ding G 2026 · Front Nutr | RCT | mixed | moderate | Prediabetic older adults with hypomagnesemia (RCT): oral Mg improved glycemic parameters vs placebo. |
| Navarrete-Cortes A, Ble-Castillo JL, Guerrero-Romero F, Cordova-Uscanga R, Juárez-Rojop IE, Aguilar-Mariscal H, Tovilla-Zarate CA, Lopez-Guevara Mdel R 2014 · Magnes Res | RCT | contradicts | moderate | Normomagnesemic T2D crossover RCT (n=98): NO change in fasting glucose, HbA1c, insulin or HOMA-IR — no benefit absent deficiency. ↩ SUPERSEDED — pooled in the review above, counted once |
| Song Y, He K, Levitan EB, Manson JE, Liu S 2006 · Diabet Med | meta-analysis | supports | moderate | MA of double-blind RCTs: oral Mg lowered fasting glucose in T2D. |
| Almajed N, Al-Musharaf S, Aldhwayan MM, Mazi TA, AlShammari SS, Almadani FA, Aljuraiban GS 2025 · International journal of general medicine | observational | supports | low | Cross-sectional n=1009 Saudi adults; low serum Mg (<1.7mg/dL) independently assoc. w/ prediabetes OR=1.9 (95% CI 1.3-2.8) |
| Kazemi A, Ryul Shim S, Jamali N, Hassanzadeh-Rostami Z, Soltani S, Sasani N, Mohsenpour MA, Firoozi D, Basirat R, Hosseini R, Clark CCT, Babajafari S, Soltanmohammadi M 2022 · Diabetes Res Clin Pract | meta-analysis | mixed | moderate | Network MA of nutritional supplements for glycemic control: Mg among effective agents but not top-ranked across all glycemic markers. |
| Fatima Zaidi SN, Yasmeen K, Alshahrani SM, Akhtar S, Shahid SM, Rehman ZU 2026 · Current pharmaceutical biotechnology | animal | supports | low | Fructose-induced T2DM rats; MgSO4 tx significantly (p<0.05) reduced insulin, insulin resistance vs diabetic controls |
| Veronese N, Watutantrige-Fernando S, Luchini C, Solmi M, Sartore G, Sergi G, Manzato E, Barbagallo M, Maggi S, Stubbs B 2016 · Eur J Clin Nutr | meta-analysis | supports | moderate | MA 18 RCTs (diabetes/high-risk): Mg reduced fasting plasma glucose (SMD -0.40). |
Disagree, or know a study we missed?
We grade by evidence, not opinions. The way to weigh in is to point us to a study we haven't cited (check the evidence table above first), or to flag a problem with one we have. Every submission is reviewed; if it holds up, the grade updates and shows in Science Changes Its Mind.
Opens a short form. You'll sign in with Google so submissions are tied to a real account — we don't display your identity, and we only accept a link we can verify (PubMed, DOI, ClinicalTrials.gov).
Educational only, not medical advice. Grades and scores reflect published evidence weighted by study design and quality; see the methodology.